Kimelman & Baird LLC Makes New $17.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Kimelman & Baird LLC acquired 27,671 Regeneron shares in the second quarter, valued at approximately $17.25 million. Institutional investors collectively own 83.31% of the company.
• Regeneron reported quarterly earnings of $14.29 per share, exceeding the $10.16 consensus estimate, while revenue rose 16.7% year over year to $4.29 billion.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $800.36; the company also announced a quarterly dividend of $0.94 per share, a 0.5% annualized yield.

Kimelman & Baird LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 27,671 shares of the biopharmaceutical company's stock, valued at approximately $17,254,000.

Several other institutional investors have also added to or reduced their stakes in the company. Insigneo Advisory Services LLC lifted its position in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock valued at $343,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital lifted its stake in Regeneron Pharmaceuticals by 3.2% in the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company's stock worth $353,000 after purchasing an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its holdings in Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock valued at $342,000 after acquiring an additional 14 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock worth $130,000 after purchasing an additional 15 shares during the last quarter. Finally, MCF Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director owned 603 shares of the company's stock, valued at $482,400. This trade represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 over the last 90 days. 6.97% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $794.19 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm has a market cap of $81.77 billion, a PE ratio of 19.63, a P/E/G ratio of 1.37 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The stock has a fifty day moving average price of $717.52 and a 200-day moving average price of $718.38.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the previous year, the business earned $12.81 EPS. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is 9.29%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada lifted their target price on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the company a "sector perform" rating in a research report on Friday, July 31st. HSBC dropped their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating on the stock in a research report on Monday, July 6th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 15th. Truist Financial upped their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Guggenheim raised their price objective on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Fifteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $800.36.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source